Cipla Q4 Results Review: Dolat Capital Maintains 'Add' Rating, Hikes Target Price — Here's Why

Dolat Capital believes that ex Revlimid margin trajectory will sustain from focus on differentiated launches in the US and traction in the South Africa business and One India business. Earlier than expected launches of gAbraxane or gAdvair will be an upside to the brokerage's estimates.